AbbVie Inc. FDA Record

Warning letters, Form 483s, inspections, recalls and 510(k) clearances

  • Latest inspection NAI · Apr 27, 2026
  • No warning letters matched by name
Inspections 52 0 OAI
Recalls 20 0 Class I (0%)
Warning letters 0 None on file
510(k) clearances 7 Latest Jan 16, 2026

AbbVie Inc. has 20 FDA recalls, 52 inspections, 7 510(k) clearances and 0 compliance actions on record. No FDA warning letter addressed to "AbbVie Inc." is on file.

What these totals cover: FDA records filed under the name "AbbVie Inc." and its spelling variant "Abbvie". Records filed under related names are not included; see Related names.

Latest recall
D-0551-2026 · Class III · May 18, 2026
Latest inspection
Apr 27, 2026 · NAI
Latest 510(k)
Jan 16, 2026

Summary

Record counts and when each FDA source was last refreshed
RecordsCountLast refreshedSource as ofStatus
Recalls20Drug: Nov 20, 2026 (checked Nov 22, 2026, unchanged); Device: Nov 20, 2026 (checked Nov 22, 2026, unchanged); Food: Nov 22, 2026Drug: File dated Nov 19, 2026; Device: File dated Nov 19, 2026; Food: File dated Nov 19, 2026Current
510(k) clearances7Nov 22, 2026File dated Nov 18, 2026Current
Inspections52Nov 22, 2026Newest record Nov 9, 2026Current
Compliance actions0Nov 22, 2026Newest record Nov 13, 2026Current

FDA record by year

AbbVie Inc.'s FDA inspections, warning letters and recalls in each of the last 10 calendar years (2017 to 2026, 2026 so far).

AbbVie Inc.: FDA inspections per year

2017: 1 inspection (0 OAI), 0 warning letters, 6 recall records (0 Class I) 2018: 6 inspections (0 OAI), 0 warning letters, 1 recall record (0 Class I) 2019: 1 inspection (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2020: 1 inspection (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2021: 1 inspection (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2022: 2 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2023: 2 inspections (0 OAI), 0 warning letters, 1 recall record (0 Class I) 2024: 3 inspections (0 OAI), 0 warning letters, 2 recall records (0 Class I) 2025: 3 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2026: 3 inspections (0 OAI), 0 warning letters, 1 recall record (0 Class I)
YearInspectionsOAIWarning lettersRecall recordsClass I
202630010
202530000
202430020
202320010
202220000
202110000
202010000
201910000
201860010
201710060

Inspections are counted by the date they ended, warning letters by the date FDA issued them and recall records by the recall start date. FDA lists one recall record per recalled product, so one recall event can add several.

Reviewing AbbVie Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check AbbVie Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Recent recalls

20 recall records from Aug 1, 2013 to May 18, 2026.

NumberClassProductDate
D-0551-2026Class IIIPRED MILD, prednisolone acetate ophthalmic suspension, USP, 0.12%, 10 mL, Sterile, Rx only…May 18, 2026
D-0665-2024Class IIRefresh LACRI-LUBE, (42.5% Mineral Oil, 57.3% White Petrolatum) Lubricant Eye Ointment, Net wt, 0.12…Sep 16, 2024
D-0664-2024Class IIRefresh P.M., (Mineral Oil 42.5%, White Petrolatum 57.3%) Lubricant Eye Ointment, Net wt, 0.12 oz…Sep 16, 2024
D-0088-2024Class IIISynthroid, Levothyroxine Sodium Tablets, USP 125mcg (0.125mg), 100-count bottle, Rx Only AbbVie Inc…Oct 17, 2023
D-0412-2018Class IIIUltane (sevoflurane), 250 mL, Inhalation Anesthetic, Rx only, Manufactured by: AbbVie Inc., North…Jan 22, 2018
D-0034-2018Class IIIAndroGel (testosterone gel) 1.62%, 40.5mg in 2.5g aluminum foil packet, 30 Packets per carton. Rx…Sep 8, 2017
D-0033-2018Class IIIAndroGel (testosterone gel) 1.62%, 88 gm metered-dose pump, 20.25 mg of testosterone per pump…Sep 8, 2017
Z-2177-2017Class IIAbbVie PEG, PEG Kit 15FR, FOR ENTERAL USE ONLY, STERILE, Rx Only.Apr 27, 2017
Z-2176-2017Class IIAbbVie PEG, PEG Kit 20FR, FOR ENTERAL USE ONLY, STERILE, Rx Only.Apr 27, 2017
Z-2178-2017Class IIAbbVie PEG, PEG Kit 15FR, FOR ENTERAL USE ONLY, STERILE, Rx Only.Apr 27, 2017
D-0495-2017Class IIDuopa (carbidopa and levodopa enteral suspension), 4.63 mg/20 mg per mL, 100 mL cassette, 7…Jan 13, 2017
Z-0786-2017Class IIAbbVie PEG Kit 20 FRNov 22, 2016
D-0833-2016Class IIIZemplar (paricalcitol) capsules, 1 mcg, 30-count bottle, Rx Only, Mfd for AbbVie Inc. North Chicago…Mar 24, 2016
D-1611-2014Class IICREON (pancrelipase) Delayed-Release Capsules, Lipase 24,000 USP Units, 250 Capsule Bottles, Rx…Sep 15, 2014
D-1288-2014Class IILupron Depot (Leuprolide Acetate for Depot Suspension) Single Dose Administration Kit with prefilled…Mar 10, 2014
D-1291-2014Class IILupron Depot (Leuprolide Acetate for Depot Suspension) Single Dose Administration Kit with prefilled…Mar 10, 2014
D-1289-2014Class IILUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension) Single Dose Administration Kit with…Mar 10, 2014
D-1287-2014Class IILupron Depot (Leuprolide Acetate for Depot Suspension) Single Dose Administration Kit with prefilled…Mar 10, 2014
D-1290-2014Class IILupron Depot (leuprolide acetate for depot suspension) Single Dose Administration Kit with prefilled…Mar 10, 2014
D-901-2013Class IIIMavik¿ trandolapril tablets 4mg, 100 count bottle, Rx only, Manufactured by Halo Pharmaceutical…Aug 1, 2013

Recent FDA inspections

52 inspections from Jan 16, 2009 to Apr 27, 2026. Showing the 20 most recent. View all 52 inspections

DateSiteProductClassificationFEI
Apr 27, 2026North Chicago, ILDrugsNo Action Indicated (NAI)3009751352
Apr 2, 2026North Chicago, ILDrugsNo Action Indicated (NAI)3009751352
Mar 3, 2026North Chicago, ILDrugsNo Action Indicated (NAI)1411365
Aug 21, 2025North Chicago, ILDrugsNo Action Indicated (NAI)3009751352
Jun 12, 2025North Chicago, ILBiologicsNo Action Indicated (NAI)3009751352
Jan 24, 2025Aprilia, ItalyDrugsVoluntary Action Indicated (VAI)3002806277
Jun 18, 2024North Chicago, ILDrugsVoluntary Action Indicated (VAI)1411365
Apr 19, 2024North Chicago, ILDrugsNo Action Indicated (NAI)3009751352
Apr 18, 2024Barceloneta, PRDrugsVoluntary Action Indicated (VAI)3000210838
May 12, 2023Wyandotte, MIDrugsNo Action Indicated (NAI)3010166391
Jan 31, 2023North Chicago, ILVeterinaryVoluntary Action Indicated (VAI)3009751352
Oct 6, 2022North Chicago, ILDrugsNo Action Indicated (NAI)3009751352
May 20, 2022Aprilia, ItalyDrugsVoluntary Action Indicated (VAI)3002806277
Dec 15, 2021North Chicago, ILDrugsVoluntary Action Indicated (VAI)3009751352
Feb 20, 2020Barceloneta, PRDrugsVoluntary Action Indicated (VAI)3000210838
Feb 15, 2019North Chicago, ILDrugsNo Action Indicated (NAI)3009751352
Dec 21, 2018Barceloneta, PRDrugsNo Action Indicated (NAI)3000210838
Nov 16, 2018North Chicago, ILDrugsNo Action Indicated (NAI)3009751352
Nov 15, 2018Aprilia, ItalyDevicesNo Action Indicated (NAI)3002806277
Aug 24, 2018North Chicago, ILVeterinaryNo Action Indicated (NAI)1411365
NAI
No objectionable conditions or practices were found during the inspection.
VAI
Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
OAI
Regulatory and/or administrative actions are recommended.

Look up the inspector observations behind these results with the FDA 483 search, or check for formal enforcement with the FDA warning letter search.

FDA-inspected facilities

6 inspected sites, newest inspection first.

FacilityLocationInspectionsLatest
FEI 3009751352North Chicago, IL20Apr 27, 2026
FEI 1411365North Chicago, IL10Mar 3, 2026
FEI 3002806277Aprilia, Italy6Jan 24, 2025
FEI 3000210838Barceloneta, PR9Apr 18, 2024
FEI 3010166391Wyandotte, MI6May 12, 2023
FEI 3010757606North Chicago, IL1Dec 16, 2014

Recent 510(k) clearances

7 510(k) clearances from Jun 18, 2014 to Jan 16, 2026.

K-NumberDeviceDate
K254126Natrelle 133S Tissue ExpandersJan 16, 2026
K142816AbbVie JJan 14, 2015
K142792AbbVie NJJan 14, 2015
K142793AbbVie PEGJan 14, 2015
K133129ABBVIE NJJun 19, 2014
K133087ABBVIE PEGJun 19, 2014
K133096ABB VIE JJun 18, 2014

AbbVie Inc. and the FDA: common questions

Has AbbVie Inc. received an FDA warning letter?

No FDA warning letter addressed to the name "AbbVie Inc." is on file. This answer covers that name only: letters addressed to a related company name or to one of its sites are listed on that name's or site's own page.

Has AbbVie Inc. received an FDA Form 483?

FDA has not published a Form 483 for "AbbVie Inc." in its reading room. FDA publishes some Form 483s, not all of them.

When did the FDA last inspect AbbVie Inc.?

The most recent FDA inspection on file ended Apr 27, 2026 at North Chicago, IL and was classified NAI. FDA has 52 inspections of AbbVie Inc. on file.

Has AbbVie Inc. had an FDA recall?

Yes. AbbVie Inc. has 20 FDA recalls on record. The most recent started May 18, 2026.

Need more than this page shows? Ask about AbbVie Inc. in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.

Get a free API key

Prefer a PDF? Request a free supplier snapshot.

Is this your company or a supplier you list? Link to this FDA record from your site with a free button.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.